We investigated the effects of a chicken collagen hydrolysate (CCH) on the circulation system in humans. A total of 58 subjects with either mild hypertension (systolic blood pressure (SBP) of 140-159 mmHg or diastolic blood pressure (DBP) 90-99 mmHg) or highnormal blood pressure (SBP 130-139 mmHg or DBP 85-89 mmHg) were assigned to two groups, one involving a placebo and the other, the test food (including CCH of 2.9 g/d). The parameters related to each subject's circulation system were monitored over the study period of 18 weeks. The Ábrachial-ankle pulse wave velocity (baPWV), an indicator of arterial stiffness and marker of vascular damage, was significantly lower in the test food group than in the placebo group during the treatment period. The blood pressure in the test food group was also significantly lower than that in the placebo group, while the serum nitrogen oxide was higher in the test food group after the treatment. These results suggest that CCH exerted modulatory effects on the human circulation system. Key words: collagen peptides; circulation system; angiotensin converting enzyme (ACE)-inhibitory activity; brachial-ankle pulse wave velocity (baPWV); arterial stiffness
Collagen is one of the main proteins in living organisms and accounts for approximately one-third of all protein in the bodies of mammals, including humans. It takes the form of an extracellular matrix that plays a role in the formation of connective tissues and as a scaffold for cells.
Collagen peptides have been used as a functional food. There have been a large number of subjective reports on the intake of collagen peptides improving such skin disorders as rough and dry skin. 1) Vigorous research has also been conducted to elucidate both the physiological functions and mechanism of action of collagen peptides. It has been shown that orally administered collagen peptides were transferred to the blood in the form of di-or tri-peptides, without complete degradation to amino acids. [2] [3] [4] Furthermore, these di-or tri-peptides, which are present in human peripheral blood after ingesting collagen peptides, had physiological functions. [2] [3] [4] The growing body of evidence on the physiological functions of ingested collagen peptides prompted us to investigate their effects on the circulation system. [5] [6] [7] An intake of 2.9 g/d of a chicken collagen hydrolysate (CCH), which had been extracted from chicken legs, over 12 weeks had an antihypertensive effect when compared with that on a placebo group. 5) We also found that the administration of CCH (5.2 g/d) for 4 weeks significantly decreased SBP by 11.8 mmHg in mildly hypertensive subjects. In addition, the activation of endothelial progenitor cells in the peripheral blood was confirmed in subjects who had ingested 5.2 g of CCH daily for 4 weeks.
6) The number of endothelial progenitor cells has been reported to be negatively correlated with the presence of coronary risk factors, and to be positively correlated with the vascular endothelial function. 8) A rat model of cardiovascular damage has confirmed that the intake of CCH for 8 weeks improved vascular relaxation. 7) These results suggest that a wide variety of protective effects on the circulation system, as well as antihypertensive activity, can be expected from the intake of CCH.
However, the dosage of CCH (5.2 g/d) used in our previous study was high. We found, by comparing three doses (1.4, 2.9, and 4.4 g/d) of CCH in mildly hypertensive subjects, that the most appropriate dose of CCH was 2.9 g/d. 9) That study was also conducted without setting a placebo group. Therefore, in this present study, we performed a double-blind placebo-controlled evaluation by using a CCH dose of 2.9 g/d to test for further protective effects of CCH on the circulation system.
Materials and Methods
Subjects. The subjects (30 males and 28 females) were randomly selected from among 120 people with mild hypertension (a systolic y To whom correspondence should be addressed. Fax: +81-29-847-7823; E-mail: t.kouguchi@nipponham.co.jp Abbreviations: CCH, chicken collagen hydrolysate; SBP, systolic blood pressure; DBP, diastolic blood pressure; baPWV, brachial-ankle pulse wave velocity; NOx, nitrogen oxide; BMI, body mass index; IRB, institutional review board; A/G ratio, albumin to globulin ratio; ALT, alanine transaminase; AST, aspartate transferase; -GTP, -glutamyltransferase; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; HDL, high-density lipoprotein; HbA1c, hemoglobin A1c; ACE, angiotensin converting enzyme; eNOS, endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase blood pressure (SBP) of 140-159 mmHg or diastolic blood pressure (DBP) of 90-99 mmHg) or high-normal blood pressure (SBP of 130-139 mmHg or DBP of 85-89 mmHg) who had not been treated with any antihypertensive agents.
The 58 subjects were randomly assigned to two groups on the basis of measurements determined during the observation period before administering the experimental diets. No significant differences in subject characteristics such as sex, age, body height, body weight, body mass index (BMI), SBP, DBP, and pulse rate existed between the two groups ( Table 1) .
The study was conducted after acceptance by the institutional review board (IRB) for clinical trial services at Soiken Inc. (Osaka, Japan) and was performed under inspection by the study investigators. The subjects were informed on the test contents and methods by the study investigators and provided their written informed consent, thus protecting their rights in accordance with the spirit of the Declaration of Helsinki.
Experimental diets. A lactic acid bacterial beverage containing CCH (test food) and its counterpart without CCH (placebo) were used as the experimental diets. CCH was obtained by using a procedure essentially based on the method of Saiga et al. 6) First, gelatin was extracted from chicken legs and purified by filtration. The extracted gelatin was then degraded with proteases, sterilized, and dried. Each experimental diet was prepared in the form of a 120-mL lactic acid drink. The test food contained 2.9 g of CCH. The placebo lactic acid drink was identical to the test food but without CCH. IRB confirmed there to be no difference in taste or texture between these supplementary drinks. Table 2 shows the compositions of CCH and the experimental diets.
Trial design. The trial was designed as a placebo-controlled, double-blind, parallel-group comparison study. The 18-week study period comprised 2 weeks for pre-treatment observation, 12 weeks for treatment, and 4 weeks for post-treatment observation (Fig. 1) . All the subjects were given a bottle of lactic acid drink daily during the treatment period. The subjects in the test-food group were given the test food containing CCH at 2.9 g/d, while the subjects in the placebo group were given the same lactic acid drink, but without CCH. All the subjects in the two groups were directed not to change their daily diets or exercise regimens. Eleven study visits were scheduled: À2 and À1 wk (the pre-treatment observation period); 0, 2, 4, 6, 8, 10, and 12 wk (the treatment period); and þ2 and þ4 wk (the post-treatment observation period). The subjects attended each of these visits after fasting for more than 10 h following supper on the day before the visit, and were examined and interviewed by a doctor, or by a nurse under the supervision of a doctor.
Body height and body weight. Body height was determined by a preliminary physical examination. Body weight was measured a total of six times: once during the pre-treatment observation period (À2 wk), 4 times during the treatment period (0, 4, 8, and 12 wk), and once during the post-treatment observation period (þ4 wk). The measured values were used to calculate BMI on each day of the study visit.
Blood pressure and pulse rate. Blood pressure and pulse rate were determined at all visits. Blood pressure was measured more than once by using a mercury manometer. An average value of 2 stable The 58 subjects were assigned to two groups and given the test food or a placebo for 12 weeks. Eleven study visits were scheduled: À2 and À1 wk (the pre-treatment observation period); 0, 2, 4, 6, 8, 10, and 12 wk (the treatment period); and þ2 and þ4 wk (the post-treatment observation period). Arrowheads show the time for clinical and laboratory examinations. CCH, chicken collagen hydrolysate; baPWV, brachialankle pulse wave velocity. measurements (the difference in values being less than 5 mmHg) was used as the value recorded. Pulse rate was measured once at each visit.
Brachial-ankle pulse wave velocity (baPWV). baPWV was determined by using a BP-203RPE II automatic pulse wave analyzer (Omron Colin Co., Kyoto, Japan) in accordance with the manufacturer's instructions at 0, 4, 8, and 12 wk. The subjects were examined in the supine position with four cuffs wrapped on both brachia and ankles (Fig. 2) . Each pulse wave to the brachia and ankles was measured. The time interval between the wave front of the brachial waveform and that of the ankle waveform is defined as ÁTba. The distances from the heart to brachium (Lb) and ankle (La) were calculated on the basis of the subject's body height. baPWV was calculated from the following equation: baPWV ¼ ðLa À LbÞ=ÁTba.
Hematological examinations. Hematological examinations were conducted a total of three times: twice during the treatment period (0 and 12 wk) and once during the post-treatment observation period (þ4 wk). The laboratory parameters tested were the erythrocyte, leukocyte, and platelet counts; hemoglobin, hematocrit, blood glucose, total protein, albumin, albumin-to-globulin ratio (A/G ratio), total cholesterol, neutral fat, alanine transaminase (ALT), aspartate transferase (AST), -glutamyltransferase (-GTP), lactate dehydrogenase (LDH), alkaline phosphatase (ALP), total bilirubin, high-density lipoprotein (HDL) cholesterol, creatinine, uric acid, urea nitrogen, sodium, chloride, potassium, calcium, magnesium, hemoglobin A1c (HbA1c), and renin activity. In addition, the serum nitrogen oxide (NOx) level was quantified as an arteriosclerosis-related parameter at 0 and 12 wk. The subjects fasted for 10 h or more following supper on the day before the blood tests to minimize any extraneous dietary influences on the test results. Blood was collected in the sitting position after more than 10 min of rest in that position.
Urinalysis. The urine examination was conducted a total of three times: twice during the treatment period (0 and 12 wk) and once during the post-treatment observation period (þ4 wk). Among the parameters investigated, sodium, potassium, chloride, and creatinine were quantified. Urine test strips were used to detect pH, protein, glucose, urobilinogen, and occult blood, and specific gravity was determined by refractometry. The daily (24 h) excretion of urinary sodium and potassium was determined by using spot samples of urine. 10, 11) Consultations. Each subject was interviewed by a doctor on all visit days to investigate any presence of such symptoms and adverse events as a dry cough, headache, dizziness, gastric problems, eruptions, skin itching, or taste disorders. The subjects were continuously monitored until the symptoms had disappeared if any adverse events had been reported or observed.
Statistical analysis. All the values measured are shown as the mean AE standard deviation, with the mean AE standard error used only in the case of figures. The unpaired Student's t-test was used for comparisons between the two experimental groups for all laboratory parameters. The paired Student's t-test (two measurements) or Bonferroni's multiple-comparison test (more than two measurements) was used to compare baseline values or those taken at 0 wk of treatment with those taken on the other study visit days to detect timedependent changes in these values. The interaction between the type of experimental diet and the duration of administration in the case of baPWV was also investigated by two-way-layout ANOVA. The statistical software used was SPSS Ver. 11.5 (IBM Corp., New York, USA), the level of significance being p < 0:05 (for the two-sided test). Values with a significance level of p < 0:1 were also reported as a trend toward significance for such primary endpoints as the blood pressure, baPWV, and serum level of NOx as arteriosclerosis-related parameters.
Results

Body weight and BMI
A comparison between the effect of the two experimental diets revealed no significant difference in either the body weight or BMI (data not shown).
Blood pressure and pulse rate Changes in SBP, DBP, and pulse rate are shown in Table 3 . SBP in the test food group was significantly lower after 12 weeks than in the placebo group. SBP after the treatment was significantly lower in the test food group than the baseline value after 2, 4, 6, 8, 10, and 12 wk. There was no significant change in SBP in the placebo group. DBP in the test food group showed a decreasing trend after 2 and 12 wk when compared with the values in the placebo group. The pulse rate in the test food group also showed a decreasing trend after 4, 12, and þ2 wk when compared with the values in the placebo group. baPWV Table 4 shows changes in baPWV. A significant relationship between the type of experimental diet and duration of intake was apparent for baPWV (right). The baPWV values (right) during the treatment period after 8 wk and 12 wk in the placebo group were greater than at 0 wk. There were also significant increases after 4, 8, and 12 wk for the baPWV values (left) in the placebo group when compared with the value at 0 wk. In addition, baPWV (average) in the placebo group showed an increase 4, 8, and 12 wk after the start of treatment when compared with the initial value. Figure 3 shows a comparison of the changes in Á value against the measurements taken at 0 wk of treatment.
Blood and urine examinations
All hematological and urine measurements remained within the standard ranges (data not shown). It is important to note that the serum NOx value after 12 wk was higher (p < 0:1) than at 0 wk in the test food group, but not in the placebo group (Fig. 4) .
Consultations and interviews
There were no adverse events associated with the intake of either experimental diet. The subjects were examined in the supine position with four cuffs wrapped on both the brachia and ankles. ÁTba is the time interval between the wave front of the brachial waveform and that of the ankle waveform. Lb and La are the respective distances from the heart to the brachium and ankle. baPWV ¼ ðLa À LbÞ=ÁTba. The pulse wave velocity is low in a flexible aorta, the baPWV value being small. The velocity is high in an inflexible aorta, the baPWV value becoming large. baPWV, brachial-ankle pulse wave velocity.
Discussion
Angiotensin converting enzyme (ACE) inhibitors can reduce the vasopressive effect of angiotensin II by inhibiting the ACE-mediated biosynthesis of angiotensin II. They can also simultaneously inhibit kininase II (the bradykinin catabolic enzyme), resulting in an increase in the bradykinin level. Bradykinin promotes NO production by activating endothelial nitric oxide synthase (eNOS). NO increases the blood flow by relaxing the vascular smooth muscles and thus expanding the arteries (i.e., by the vasodilating effect); it also inhibits platelet adhesion to the vascular endothelium and platelet aggregation. In addition, angiotensin II directly promotes the proliferation of vascular smooth muscle cells.
12) ACE inhibitors can thus be expected to have both an antihypertensive effect and vasoprotective activity that act against arteriosclerosis. 13) CCH activates endothelial progenitor cells 6) and promotes vascular relaxation. 7) We therefore measured baPWV in 58 subjects with mild hypertension or highnormal blood pressure. baPWV is used by medical institutions as an indicator of the arterial stiffness value and as a marker of vascular damage. [14] [15] [16] [17] Those subjects with a flexible aorta show a low baPWV value, because the value reflects the aorta flexibility. [14] [15] [16] baPWV is associated with aging and sex: aging is positively correlated with baPWV, and males tend to show a higher baPWV value than females. 18) A cut-off value of 1400 cm/s has been proposed as an index of cardiovascular disease in Japan. 14) All baPWV values in the placebo group (right, left, and average) significantly increased with time (Table 4) . baPWV is also known to be higher in the winter than in the summer. 19) We speculate that the time-dependent increase in baPWV observed in the placebo group was due to seasonal variation, since the study was conducted from July to December. On the other hand, the baPWV values for the test food group did not significantly change (Table 4 ). These data suggest that the intake of CCH improved arterial flexibility more effectively than that of the placebo.
A trend toward an increase in the serum level of NOx, a metabolite of NO, was found in the test food group after 12 wk when compared with that at 0 wk (Fig. 4) . This might be supported by our previous data indicating that a CCH administration increased the serum NO concentration in rats. 7) Since NO inhibits the proliferation of vascular smooth muscle cells, CCH might facilitate the NO-induced inhibition of arteriosclerosis in humans. However, further studies are required to fully elucidate this increase in NOx level.
Vascular protection is important to improve and maintain the quality of life. The mortality rates in countries such as the USA, England, Germany, and France from cardiovascular diseases, including myocardial infarction and cerebral infarction, are greater than those from malignant neoplasms. There have been some reports on foods with vasoprotective activity: peptides derived from sardine, 20) sesame, 21) and milk casein 22) had ACE-inhibitory activity, and a pine bark extract increased the blood flow and exerted a vasorelaxant effect. 23) However, there are few reports of a diet-attributable improvement in baPWV. CCH also showed both a SBP, systolic blood pressure; DBP, diastolic blood pressure hypotensive action and the effect of improving baPWV. We have previously shown that orally-administered CCH was transferred to the blood in the form of such bioactive dipeptides as Pro-Hyp and Hyp-Gly in humans.
2) In our previous study, these peptides reduced the expression of such inflammation markers as ICAM-1, VCAM-1, IL-8, and inducible nitric oxide synthase (iNOS) which were up-regulated by TNF-. 24) These results suggest that the modulatory effects of CCH on the circulation system, for example the improvement of arterial flexibility, might be due to the inhibition of endothelial inflammation.
Unlike pharmaceuticals that are specifically prescribed by physicians, foods, and particularly functional foods, should be freely chosen by consumers, and should simultaneously confer benefits similar to those of pharmaceuticals. We conclude that CCH would be a useful functional food with a modulatory effect on the circulation system that contributes to the maintenance of health. 
